Maciej Mrugala, MD
Neurology · Scottsdale, AZNPI 1376533620
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $83,866 of the $97,325 with a category attached, or 86.2%. 10 manufacturers reported payments, led by AstraZeneca at 59.9% of the total. Among neurology clinicians in AZ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 77 payments — averaging $1263.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$58K
- Springworks Therapeutics, Inc.$15K
- SK Life Science, Inc.$5K
- Merck$5K
- Menarini Silicon Biosystems, Inc.$4K
- Novocure Inc.$3K
- plus $7K from 4 others
Across 32 payments — averaging $4987.01 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim$105K
- Arbor Pharmaceuticals, Inc.$16K
- Azurity Pharmaceuticals, Inc.$15K
- Jazz Pharmaceuticals Inc.$11K
- Boehringer Ingelheim International GmbH$8K
- Springworks Therapeutics, Inc.$6K
What the payments were for
- Consulting fees$83,86686%
- Speaking & faculty fees$3,9004%
- Grants$2,6183%
- Travel & lodging$4,3464%
- Food & beverage$2,5943%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 33 | $58,257 |
| Springworks Therapeutics, Inc. | 15 | $14,630 |
| SK Life Science, Inc. | 7 | $5,362 |
| Merck | 4 | $5,238 |
| Menarini Silicon Biosystems, Inc. | 2 | $4,200 |
| Novocure Inc. | 5 | $2,969 |
| Servier Pharmaceuticals LLC | 6 | $2,670 |
| Telix Pharmaceuticals | 3 | $2,619 |
| Biogen | 1 | $1,315 |
| AbbVie | 1 | $65 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$97,325 in reported general payments places this provider in the 90th percentile of 388 neurology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 11 | $6,192 |
| Levetiracetam | 44 | $1,367 |
| Dexamethasone | 27 | $522 |
| Memantine Hcl | 15 | $454 |
| Lacosamide | 17 | $369 |
| Gabapentin | 21 | $293 |
| Prochlorperazine Maleate | 12 | $110 |
| Ondansetron Hcl | 17 | $76 |
| Sertraline Hcl | 14 | $64 |
Paid to pharmacies, not to this prescriber.
Other neurology in Scottsdale
- Nida LaurinScottsdale$969K
- Dean WingerchukScottsdale$324K
- Amaal StarlingScottsdale$315K
- Virgilio Gerald EvidenteScottsdale$231K
- Brent GoodmanScottsdale$198K
- David SapersteinScottsdale$135K
- Charles AdlerScottsdale$74K
- Jill RauScottsdale$59K
- Shyamal MehtaScottsdale$50K
- Jonathan CarterScottsdale$44K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.